FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1116-1117 October 3, 2002 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gale, E. A.M. Related Article by Herold, K. C. PubMed Citation

To the Editor: The report by Herold et al. (May 30 issue)¹ on the use of anti-CD3 monoclonal antibody in patients with new-onset type 1 diabetes and the accompanying editorial by Gale² leave important questions unanswered. The authors suggest that treatment with anti-CD3 antibody mitigates the deterioration in insulin production and improves metabolic control. Moreover, they suggest that because of differences in the glycosylated hemoglobin levels between the treatment and control groups at entry, the true effect of the antibody treatment may even have been greater than that reported.

I would suggest a different possibility: regression toward the mean. It . . . [Full Text of this Article]

This article has been cited by other articles:

• TARGAN, S. R (2006). Current Limitations of IBD Treatment: Where Do We Go from Here?. Ann. N. Y. Acad. Sci. 1072: 1-8 [Abstract] [Full Text]